Prevention of hypertension attenuates albuminuria and renal expression of fibronectin in diabetic spontaneously hypertensive rats.
OBJECTIVE
The aim of this study was to evaluate the effect of preventing hypertension on renal disease in a model of genetic hypertension and diabetes.


METHODS
Four-week-old spontaneously hypertensive rats (SHR) with streptozotocin-induced diabetes were randomized for no treatment, or for treatment with captopril, losartan or triple therapy (hydrochlorothiazide, reserpine and hydralazine) for 16 weeks.


RESULTS
Increase in systolic blood pressure was equally prevented by captopril (128 +/- 3 mm Hg), losartan (128 +/- 2) and triple therapy (129 +/- 2, p < 0.0001). Albuminuria was similarly reduced by captopril (499 (404-659)), losartan (622 (470-976)) and triple therapy (479 (362-600) microg/24 h (p < 0.0001)). Renal fibronectin expression increased in diabetic SHR (125 +/- 13 densitometric unit) as compared to the controls (51 +/- 9, p < 0.0001), and decreased (p < 0.0001 vs. diabetic SHR) with captopril (32 +/- 8), losartan (27 +/- 4) and triple therapy (35 +/- 6).


CONCLUSIONS
The prevention of hypertension in diabetic SHR by captopril, losartan or triple therapy was equally efficacious in impeding increase of albuminuria and the expression of renal fibronectin. Under these conditions, tight blood pressure control was the main determinant in attenuating nephropathy.
Pavan
M V
MV
Division of Nephrology, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas Brazil.
Ghini
B
B
Castro
M
M
Lopes De Faria
J B
JB
D000419:Albuminuria / Q000378:metabolism*; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D015153:Blotting, Western; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D005353:Fibronectins / Q000378:metabolism*; D006978:Hypertension, Renovascular / Q000378:metabolism / Q000517:prevention & control*; D007668:Kidney / Q000378:metabolism*; D007677:Kidney Function Tests; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D005353:Fibronectins